Expressing support for the designation of June 19, 2025, as "World Sickle Cell Awareness Day" in order to increase public awareness across the United States and global community about sickle cell disease and the continued need for empirical research, early detection screenings, novel effective treatments leading to a cure, and preventative care programs with respect to complications from sickle cell anemia and conditions relating to sickle cell disease.

Legislative Summary: H.Res. 524

Title: Expressing support for the designation of June 19, 2025, as "World Sickle Cell Awareness Day"

Overview

H.Res. 524 is a House Resolution aimed at increasing global and domestic public awareness of Sickle Cell Disease (SCD) and Sickle Cell Trait (SCT). The resolution designates June 19, 2025, as "World Sickle Cell Awareness Day" to advocate for improved research, early detection, and equitable access to life-saving treatments.

The bill emphasizes that SCD is a significant global health crisis, which disproportionately affects individuals of African, Hispanic, and Mediterranean descent, often leading to severe complications, organ failure, and premature death—particularly in resource-poor regions.

Key Provisions

The resolution outlines several specific goals and calls to action:

1. Public Awareness and Education

• Designation: Formally supports the designation of June 19, 2025, as World Sickle Cell Awareness Day.
• Community Action: Encourages individuals and organizations worldwide to host events and programs to educate the public on SCD traits and preventative care.
• Theme: Highlights the 2025 theme: "Global Action, Local Impact: Empowering Communities for Effective Self-Advocacy."

2. Healthcare Access and Equity

• Removing Barriers: Calls for the elimination of barriers to innovative therapies—including gene-editing and cell therapies—specifically within the Medicare and Medicaid systems to protect vulnerable populations.
• Equitable Outcomes: Commits to ensuring that treatment access is provided regardless of economic, racial, or ethnic background.

3. Government and Policy Action

• Department of Health and Human Services (HHS): Urges HHS to develop global policy solutions and partner with local governments to increase newborn screening and therapeutic interventions.
• Interagency Coordination: Encourages the President to establish a Sickle Cell Disease Interagency Group. This group would include:
  • Department of Health and Human Services (HHS)
  • Department of Veterans Affairs (VA)
  • National Institutes of Health (NIH)
  • Food and Drug Administration (FDA)
  • Centers for Medicare & Medicaid Services (CMS)
• Combating Bias: Directs the proposed interagency group to address the systemic bias and healthcare disparities faced by the populations most affected by SCD.

Who is Affected?

• Patients and Families: Individuals living with SCD or SCT, particularly those in underserved communities and developing nations.
• Healthcare Providers & Researchers: Encourages a shift toward more empirical research and the development of widely accessible cures.
• Government Agencies: Positions HHS, NIH, and CMS as primary drivers for policy change and funding for newborn screenings and innovative therapies.

Summary of Impact

If adopted, this resolution serves as a formal signal of the U.S. House of Representatives' commitment to treating Sickle Cell Disease as a public health priority. While as a resolution it expresses "support" and "encouragement" rather than mandating law, it creates a policy framework and puts pressure on federal agencies to coordinate efforts to reduce mortality rates and eliminate the racial and economic disparities associated with SCD care.